Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables: 2015-2024

Historic Receivables for Spyre Therapeutics (SYRE) over the last 1 years, with Dec 2024 value amounting to $5.9 million.

  • Spyre Therapeutics' Receivables was N/A to $5.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $39.2 million, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2024, which is N/A change from last year.
  • As of Q4 2024, Spyre Therapeutics' Receivables stood at $5.9 million, which was down 0.00% from $5.9 million recorded in Q3 2024.
  • In the past 5 years, Spyre Therapeutics' Receivables registered a high of $21.5 million during Q1 2021, and its lowest value of $5.9 million during Q2 2024.
  • For the 1-year period, Spyre Therapeutics' Receivables averaged around $5.9 million, with its median value being $5.9 million (2024).